{"organizations": [], "uuid": "1ac1de774842013fa4e2df94fa45a520ce93581d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-inflarx-receives-ind-acceptance-to/brief-inflarx-receives-ind-acceptance-to-proceed-with-a-phase-iib-trial-with-lead-candidate-ifx-1-in-hidradenitis-suppurativa-idUSASM000HY2", "country": "US", "domain_rank": 408, "title": "BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T17:42:00.000+02:00", "replies_count": 0, "uuid": "1ac1de774842013fa4e2df94fa45a520ce93581d"}, "author": "", "url": "https://www.reuters.com/article/brief-inflarx-receives-ind-acceptance-to/brief-inflarx-receives-ind-acceptance-to-proceed-with-a-phase-iib-trial-with-lead-candidate-ifx-1-in-hidradenitis-suppurativa-idUSASM000HY2", "ord_in_thread": 0, "title": "BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "hidradenitis suppurativa reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News January 9, 2018 / 3:42 PM / Updated 25 minutes ago BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa Reuters Staff 1 Min Read \nJan 9 (Reuters) - Inflarx Nv: \n* INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA \n* INFLARX NV - ‍INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-09T17:42:00.000+02:00", "crawled": "2018-01-09T17:56:03.028+02:00", "highlightTitle": ""}